Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study
Authors' conclusion
Based on standard lipid-lowering therapy, ANGPTL-3 inhibition with SHR-1918 further reduces LDL-C by 21.7% to 29.9% in patients at moderate or higher risk of ASCVD. These additional reductions are both dose and dosing frequency dependent.
Study context
- Population
- Patients at moderate or higher risk of atherosclerotic cardiovascular disease (ASCVD) with hypercholesterolaemia not at optimal low-density lipoprotein cholesterol (LDL-C) after 4 to 8 weeks of standard lipid-lowering therapy8 dose cohorts, 4:1 active/placebo
- Participants
- 333 patients
- Comparison
- SHR-1918 vs placebo
- Primary endpoint
- Percentage change from baseline in LDL-C (prespecified)
Methodological detailsmulticentre, double-blind, placebo-controlled, dose-escalation, phase 2, 16-week treatment period, then extension treatment (36 weeks Q4W, 40 weeks Q8W) and safety follow-up
- Multicentre
- Double-blind
- Placebo-controlled
- Dose-escalation
- Phase 2
- 16-week treatment period, then extension treatment (36 weeks Q4W, 40 weeks Q8W) and safety follow-up
Primary result
As reported in the abstract
Percentage LDL-C lowering vs placebo
Percentage LDL-C lowering
- 150 mg Q4W
- 21.7%
- 300 mg Q4W
- 27.3%
- 600 mg Q4W
- 29.9%
- 600 mg Q8W
- 22.5%
Further findings
Triglyceride (TG), non-HDL cholesterol, apolipoprotein B, apolipoprotein A1, LDL-C target achievement
- SHR-1918 substantially reduced TG, non-HDL cholesterol, apolipoprotein B and apolipoprotein A1, with better achievement of LDL-C targets
Safety
Tolerability
- SHR-1918 was generally well-tolerated
Original publication
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study. J Am Coll Cardiol. Published 31 March 2025. doi:10.
Summarised from the published abstract; every number is checked against it